欧州の臓器移植診断市場：分析・予測、2023-2033年

欧州の臓器移植診断の市場規模は、2023年の11億6,000万米ドルから、予測期間中は11.15%のCAGRで推移し、2033年には33億5,000万米ドルの規模に達すると予測されています。

臓器不全を引き起こす慢性疾患の急増、移植診断の利用の拡大、幹細胞治療の受け入れ拡大、移植診断検査の需要を促進する白血病患者の増加、移植診断分野における分子・ゲノム技術の進歩から得られる利点、償還制度を含む有利な規制条件の存在など、いくつかの主要な要因が同市場の成長を後押ししています。

当レポートでは、欧州の臓器移植診断の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、主要国別の詳細分析、主要企業の分析などをまとめています。

市場の分類

セグメンテーション1：国別

• ドイツ
• 英国
• フランス
• イタリア
• スペイン
• スイス
• その他

主要企業：

目次

エグゼクティブサマリー

第1章 製品の定義

第2章 市場の範囲

第3章 調査手法

第4章 概要

• 現在の市場シナリオ
  • 研究機関用途
  • 診断用途
• 市場フットプリント
• COVID-19による市場への影響

第5章 欧州

• 欧州
  • 欧州の臓器移植検査件数：移植タイプ別
  • 市場規模・予測

第6章 企業プロファイル

• 製造業者

List of Figures

• Figure 1: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
• Figure 2: Organ Transplant Diagnostics Market, Impact Analysis
• Figure 3: Organ Transplant Diagnostics Market (by Region), $Billion, 2022 and 2033
• Figure 4: Organ Transplant Diagnostics Market: Research Methodology
• Figure 5: Primary Research Methodology
• Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 7: Top-Down Approach (Segment-Wise Analysis)
• Figure 8: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
• Figure 9: Organ Transplant Diagnostics Market Share and CAGR (by Region), 2022 and 2023-2033
• Figure 10: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
• Figure 11: Europe Organ Transplant Diagnostics Market (by Country), Share (%), 2022 and 2033
• Figure 12: France Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 13: Spain Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 14: U.K. Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 15: Italy Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 16: Germany Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 17: Switzerland Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 18: Rest-of-Europe Organ Transplant Diagnostics Market, $Million, 2022-2033
• Figure 19: Total Number of Companies Profiled
• Figure 20: Organ Transplant Diagnostics Market Overview, Key Companies
• Figure 21: BAG Group GmbH: Overall Product Portfolio
• Figure 22: bioMerieux S.A.: Overall Product Portfolio
• Figure 23: bioMerieux S.A.: Overall Financials, $Million, 2019-2021
• Figure 24: bioMerieux S.A.: Net Revenue (by Region), $Million, 2019-2021
• Figure 25: bioMerieux S.A.: R&D Expenditure, $Million, 2019-2021
• Figure 26: Eurobio Scientific (Genome Diagnostics B.V.): Overall Product Portfolio
• Figure 27: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
• Figure 28: F. Hoffmann-La Roche Ltd.: Overall Financials, $Billion, 2020-2022
• Figure 29: F. Hoffmann-La Roche Ltd.: Net Revenue (by Business Segment), $Billion, 2020-2022
• Figure 30: F. Hoffmann-La Roche Ltd.: Diagnostics Revenue (by Region), $Billion, 2020-2022
• Figure 31: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Billion, 2020-2022
• Figure 32: Omixon Inc.: Overall Product Portfolio
• Figure 33: QIAGEN N.V.: Product Portfolio
• Figure 34: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
• Figure 35: QIAGEN N.V.: Net Revenue (by Business Segment), $Million, 2019-2021
• Figure 36: QIAGEN N.V.: Net Revenue (by Region), $Million, 2019-2021
• Figure 37: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021

List of Tables

• Table 1: Key Questions Answered in the Report
• Table 2: Europe Organ Transplant Diagnostics Market, Impact Analysis
• Table 3: Europe Organ Transplant Test Volume, by Transplant Type, 2021

“The Europe Organ Transplant Diagnostics Market Expected to Reach $3.35 Billion by 2033.”

Introduction to Europe Organ Transplant Diagnostics Market

In 2023, the Europe organ transplant diagnostics market was valued at $1.16 billion and is expected to reach $3.35 billion by 2033, with a CAGR of 11.15% during the forecast period 2023-2033. Several key factors are propelling growth in this sector, including a surge in the prevalence of chronic diseases resulting in organ failure, a heightened utilization of transplant diagnostics, a growing acceptance of stem cell therapy, an increase in leukemia cases driving demand for transplant diagnostic tests, the benefits derived from the advancement of molecular and genomic technologies in the field of transplant diagnostics, and the existence of favorable regulatory conditions, encompassing reimbursement schemes.

Market Introduction

The Europe organ transplant diagnostics market is experiencing significant growth driven by factors such as the increasing incidence of chronic diseases leading to organ failure. This rise in conditions like kidney, liver, and heart diseases fuels the demand for organ transplants and subsequently, transplant diagnostics. Adoption of transplant diagnostics is on the upswing due to advancements in medical technology and heightened awareness of the importance of pre-transplant compatibility testing. The growing acceptance of stem cell therapy also contributes to the demand for transplant diagnostics. Additionally, the prevalence of leukemia cases necessitates accurate diagnostic tests before bone marrow or stem cell transplantation. Advanced molecular and genomic technologies in transplant diagnostics enhance compatibility assessments. Europe's favorable regulatory environment, including reimbursement schemes, encourages investment in transplant diagnostics by healthcare providers and patients alike. These factors collectively drive growth in the Europe organ transplant diagnostics market, making it a dynamic sector for healthcare advancements.

Market Segmentation:

Segmentation 1: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Switzerland
• Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe organ transplant diagnostics market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, mergers and acquisitions, funding activities, and regulatory and legal approvals. The favored strategy for the companies has been synergistic activities such as partnerships, collaborations, expansions, and funding activities.

Competitive Strategy: The key players in the Europe organ transplant diagnostics market analyzed and profiled in the study involve established and emerging players that offer different products and services for organ transplant diagnostics. Moreover, a detailed competitive benchmarking of the players operating in the Europe organ transplant diagnostics market has been done to help the reader understand the ways in which players stack against each other, presenting a clear market landscape. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, and mergers and acquisitions will help the reader understand the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names in this market are:

Table of Contents

Executive Summary

1. Product Definition

• 1.1. Inclusion and Exclusion Criteria

2. Market Scope

• 2.1. Key Questions Answered in the Report:

3. Research Methodology

• 3.1. Organ Transplant Diagnostics Market: Research Methodology
• 3.2. Data Sources
  • 3.2.1. Primary Data Sources
  • 3.2.2. Secondary Data Sources
• 3.3. Market Estimation Model
• 3.4. Criteria for Company Profiling

4. Overview

• 4.1. Current Market Scenario
  • 4.1.1. For Researchers
  • 4.1.2. For Diagnostics
• 4.2. Market Footprint
• 4.3. COVID-19 Impact on Market
  • 4.3.1. Impact on Operations
  • 4.3.2. COVID-19 Impact: Current Scenario of Market
  • 4.3.3. Pre- and Post-COVID-19 Impact Assessment
    • 4.3.3.1. Pre-COVID-19 Phase
    • 4.3.3.2. Post-COVID-19 Phase

5. Europe

• 5.1. Europe
  • 5.1.1. Europe Organ Transplant Test Volume, by Transplant Type
  • 5.1.2. Market Sizing and Forecast
    • 5.1.2.1. Europe Organ Transplant Diagnostics Market (by Country)
      • 5.1.2.1.1. France
      • 5.1.2.1.2. Spain
      • 5.1.2.1.3. U.K.
      • 5.1.2.1.4. Italy
      • 5.1.2.1.5. Germany
      • 5.1.2.1.6. Switzerland
      • 5.1.2.1.7. Rest-of-Europe

6. Company Profiles

• 6.1. Overview
• 6.2. Manufacturers
  • 6.2.1. BAG Group GmbH
    • 6.2.1.1. Company Overview
    • 6.2.1.2. Role of BAG Group GmbH in the Organ Transplant Diagnostics Market
    • 6.2.1.3. Product Portfolio
    • 6.2.1.4. Analyst Perception
  • 6.2.2. bioMerieux S.A.
    • 6.2.2.1. Company Overview
    • 6.2.2.2. Role of bioMerieux S.A. in the Organ Transplant Diagnostics Market
    • 6.2.2.3. Product Portfolio
    • 6.2.2.4. Financials
    • 6.2.2.5. Recent Developments
    • 6.2.2.6. Analyst Perception
  • 6.2.3. Eurobio Scientific (Genome Diagnostics B.V.)
    • 6.2.3.1. Company Overview
    • 6.2.3.2. Role of Eurobio Scientific (Genome Diagnostics B.V.) in the Organ Transplant Diagnostics Market
    • 6.2.3.3. Product Portfolio
    • 6.2.3.4. Analyst Perception
  • 6.2.4. F. Hoffmann-La Roche Ltd.
    • 6.2.4.1. Company Overview
    • 6.2.4.2. Role of F. Hoffmann-La Roche Ltd. in the Organ Transplant Diagnostics Market
    • 6.2.4.3. Product Portfolio
    • 6.2.4.4. Financials
    • 6.2.4.5. Recent Developments
    • 6.2.4.6. Analyst Perception
  • 6.2.5. Omixon Inc.
    • 6.2.5.1. Company Overview
    • 6.2.5.2. Role of Omixon Inc. in the Organ Transplant Diagnostics Market
    • 6.2.5.3. Product Portfolio
    • 6.2.5.4. Analyst Perception
  • 6.2.6. QIAGEN N.V.
    • 6.2.6.1. Company Overview
    • 6.2.6.2. Role of QIAGEN N.V. in the Organ Transplant Diagnostics Market
    • 6.2.6.3. Product Portfolio
    • 6.2.6.4. Financials
    • 6.2.6.5. Recent Developments
    • 6.2.6.6. Analyst Perception